Atracsys’ fusionTrack 500 optical tracking camera will be a core enabling technology for Smith & Nephew’s multi-asset digital surgery and robotic ecosystem, including initially in its next-generation robotics platform due for commercial release in 2020. The fusionTrack 500 offers superior measurement speed and latency performance, supporting reduced procedure times, as well as increased accuracy resulting in finer precision surgical tasks, such as bone cuts, compared to existing tracking technology.
“The promise of computer assisted surgery with robotics is to provide faster, more accurate, reproducible results that enable surgeons to restore quality of life to more patients,” said Skip Kiil, global president of Orthopaedics at Smith & Nephew. “With the acquisition of Atracsys, we are securing what we believe to be the best-in-class position tracking technology for our next-generation robotic-assisted surgical system.”
Atracsys’ portfolio includes open platform optical navigation and robotic tracking components with applications in orthopaedics, neurosurgery, spine and dental. Smith & Nephew plans for the business to continue serving these markets.
“Our aim is to continuously contribute to the improvements in healthcare all around the world, guiding surgical instruments with sub-millimetric precision,” said Gaëtan Marti, co-founder and CEO of Atracsys.
“Smith & Nephew’s commitment to offer significant advancements in enabling technology across multiple surgical specialities will open breakthrough opportunities for robotics and computer-assisted surgery,” added Maurice Hälg, co-founder and chief technology officer.
The acquisition is expected to complete during the third quarter of 2019. The commercial terms have not been disclosed.
Smith & Nephew is a portfolio medical technology business that exists to restore people’s bodies, and their self-belief. Smith & Nephew has leadership positions in Orthopaedics, Advanced Wound Management and Sports Medicine, more than 16,000 employees and a presence in more than 100 countries. Annual sales in 2018 were $4.9 billion. Smith & Nephew is a member of the FTSE100.